$3.66
7.02% yesterday
Nasdaq, Aug 12, 10:16 pm CET
ISIN
US56400P7069
Symbol
MNKD

MannKind Corporation Stock price

$3.66
-0.37 9.18% 1M
-1.94 34.64% 6M
-2.77 43.08% YTD
-1.53 29.48% 1Y
-0.49 11.81% 3Y
+2.03 124.54% 5Y
-17.89 83.02% 10Y
-51.04 93.31% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.24 7.02%
ISIN
US56400P7069
Symbol
MNKD
Industry

Key metrics

Basic
Market capitalization
$1.0b
Enterprise Value
$1.2b
Net debt
$108.6m
Cash
$181.5m
Shares outstanding
303.9m
Valuation (TTM | estimate)
P/E
34.2 | 18.5
P/S
3.5 | 3.2
EV/Sales
3.9 | 3.6
EV/FCF
53.1
P/B
negative
Financial Health
Equity Ratio
-20.0%
Return on Equity
-35.0%
ROCE
27.6%
ROIC
36.7%
Debt/Equity
-4.9
Financials (TTM | estimate)
Revenue
$297.6m | $324.4m
EBITDA
$89.2m | -
EBIT
$81.1m | $87.9m
Net Income
$29.6m | $56.3m
Free Cash Flow
$21.8m
Growth (TTM | estimate)
Revenue
32.5% | 13.6%
EBITDA
149.2% | -
EBIT
161.9% | 21.1%
Net Income
251.6% | 104.1%
Free Cash Flow
603.9%
Margin (TTM | estimate)
Gross
75.8%
EBITDA
30.0% | -
EBIT
27.3%
Net
10.0% | 17.4%
Free Cash Flow
7.3%
More
EPS
$0.1
FCF per Share
$0.1
Short interest
7.9%
Employees
405
Rev per Employee
$700.0k
Show more

Is MannKind Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

MannKind Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a MannKind Corporation forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a MannKind Corporation forecast:

Buy
93%
Hold
7%

Financial data from MannKind Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
298 298
32% 32%
100%
- Direct Costs 72 72
11% 11%
24%
225 225
41% 41%
76%
- Selling and Administrative Expenses 97 97
5% 5%
33%
- Research and Development Expense 47 47
31% 31%
16%
89 89
149% 149%
30%
- Depreciation and Amortization 8.12 8.12
68% 68%
3%
EBIT (Operating Income) EBIT 81 81
162% 162%
27%
Net Profit 30 30
252% 252%
10%

In millions USD.

Don't miss a Thing! We will send you all news about MannKind Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MannKind Corporation Stock News

Neutral
Seeking Alpha
6 days ago
MannKind Corporation (NASDAQ:MNKD ) Q2 2025 Earnings Call August 6, 2025 9:00 AM ET Company Participants Christopher B. Prentiss - Chief Financial Officer Michael E.
Positive
Seeking Alpha
6 days ago
Today, we take another look at MannKind Corporation, which specializes in inhaled therapeutics for endocrine and orphan lung diseases, with a market cap of $1.15 billion. The company just reported second-quarter results and continues to enjoy universal support from the analyst firm community. MannKind saw decent growth from its two core products on the market in Q2 and just signed a new non-dil...
Positive
The Motley Fool
6 days ago
MannKind (MNKD -9.52%), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most significant news from this release was a 6% increase in total revenue to $76.53 million (GAAP), primarily from royalty gains and higher Afrezza inhaled insulin sales.
More MannKind Corporation News

Company Profile

MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.

Head office United States
CEO Michael Castagna
Employees 405
Founded 1991
Website mannkindcorp.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today